Quoin Pharmaceuticals, Ltd.

NasdaqCM:QNRX Stock Report

Market Cap: US$2.4m

Quoin Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:QNRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
10 Sep 24BuyUS$23,205Gordon DunnIndividual28,856US$0.91
04 Sep 24BuyUS$25,426Michael MyersIndividual32,572US$0.80
04 Sep 24BuyUS$28,737Denise CarterIndividual37,735US$0.80
04 Sep 24BuyUS$3,490Michael MyersIndividual5,322US$0.66
07 Jun 24SellUS$217Dennis LangerIndividual297US$0.73

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of QNRX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders123,5702.45%
Institutions165,0813.27%
General Public4,761,06994.3%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 411.5%.

Top Shareholders

Top 12 shareholders own 5.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.94%
Michael Myers
47,252US$22.9k0%no data
0.93%
Denise Carter
47,092US$22.8k0%no data
0.77%
Renaissance Technologies LLC
38,691US$18.8k13.1%no data
0.63%
Two Sigma Securities, LLC, Asset Management Arm
31,854US$15.5k35.8%no data
0.57%
Gordon Dunn
28,856US$14.0k0%no data
0.5%
Virtu Financial LLC, Asset Management Arm
25,165US$12.2k0%no data
0.5%
Raymond James Financial Services Advisors, Inc.
25,119US$12.2k0%no data
0.45%
UBS Asset Management AG
22,821US$11.1k274%no data
0.41%
Rhumbline Advisers Ltd Partnership
20,786US$10.1k40.5%no data
0.013%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
645US$312.80%no data
0.0063%
A. Culverwell
317US$153.80%no data
0.001%
Dennis Langer
53US$25.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 08:04
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Quoin Pharmaceuticals, Ltd. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Jason ButlerJMP Securities
Jason McCarthyMaxim Group